文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

美国HIV感染者与无HIV成人的疫苗接种后COVID-19突破感染重症分析

Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US.
PubMed 文献 · JAMA Netw Open · 2022-10-03
一句话结论接种后突破感染28天内重症率低(无HIV者7.3% vs HIV感染者6.7%),但CD4<350 cells/μL的HIV感染者重症风险约为无HIV者的1.59倍。

这项队列研究纳入美国4个整合健康系统与学术中心中截至2021年6月30日完成全程接种的成人HIV感染者(PWH),并按完成接种日期、年龄组、种族、民族和性别匹配无HIV者(PWoH);截至2021年12月31日发生接种后COVID-19突破感染者纳入分析,共3649例(PWH 1241例、PWoH 2408例)。突破感染后28天内重症累积发生率低且两组相近(PWoH 7.3% vs PWH 6.7%;风险差-0.67%;95%CI -2.58%至1.23%)。CD4细胞计数<350 cells/μL的PWH较PWoH重症风险高59%(aHR 1.59;95%CI 0.99至2.46;P=.049)。249例住院患者中24例(9.6%)接受机械通气、20例(8.0%)死亡,按HIV状态无差异。作者认为中度或重度免疫抑制的PWH应纳入优先追加疫苗剂量和风险降低策略的人群。

要点

  • 完成全程接种后发生COVID-19突破感染的PWH与PWoH,28天内重症累积发生率相近:PWoH 7.3% vs PWH 6.7%,风险差-0.67%(95%CI -2.58%至1.23%)。
  • CD4细胞计数<350 cells/μL的PWH突破感染后重症风险较PWoH高59%(aHR 1.59;95%CI 0.99至2.46;P=.049)。
  • PWH多因素分析中,女性、年龄较大、癌症诊断和较低CD4细胞计数与重症突破感染风险升高相关,既往COVID-19与风险降低相关。
  • 249例住院患者中24例(9.6%)接受机械通气、20例(8.0%)死亡,按HIV状态无差异。
  • 作者认为中度或重度免疫抑制的PWH应纳入优先追加疫苗剂量和风险降低策略的人群。

适用人群与场景

  • 美国4个整合健康系统与学术中心中截至2021年6月30日完成全程接种、年龄≥18岁、正在接受诊疗的HIV感染者,以及按完成接种日期、年龄组、种族、民族和性别匹配的无HIV者。
  • 2021年12月31日前发生接种后COVID-19突破感染者纳入分析。

诊断标准与关键阈值

  • 重症COVID-19突破感染定义为突破性SARS-CoV-2感染后28天内住院,且出院主要或次要诊断为COVID-19。
  • 免疫抑制分层阈值:CD4细胞计数<350 cells/μL。

研究设计与关键结果

  • 队列研究(CIVET-II协作),共3649例突破感染者(PWH 1241例、PWoH 2408例),多数年龄≥55岁(2182例[59.8%])、男性(3244例[88.9%])。
  • 突破感染后28天内重症累积发生率:PWoH 7.3% vs PWH 6.7%;风险差-0.67%(95%CI -2.58%至1.23%)。
  • CD4细胞计数<350 cells/μL的PWH较PWoH重症风险升高59%(aHR 1.59;95%CI 0.99至2.46;P=.049)。
  • PWH多因素分析中,女性、年龄较大、癌症诊断和较低CD4细胞计数与重症突破感染风险升高相关,既往COVID-19与风险降低相关。
  • 249例住院患者中24例(9.6%)接受机械通气、20例(8.0%)死亡,按HIV状态无差异。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为中度或重度免疫抑制(CD4细胞计数<350 cells/μL)的PWH突破感染后重症风险较高,应纳入优先追加疫苗剂量和风险降低策略的人群。
  • 完成全程接种的PWH与PWoH突破感染后28天内重症率均低,住院患者机械通气(9.6%)和死亡(8.0%)比例按HIV状态无差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Understanding the severity of postvaccination SARS-CoV-2 (ie, COVID-19) breakthrough illness among people with HIV (PWH) can inform vaccine guidelines and risk-reduction recommendations.

OBJECTIVE: To estimate the rate and risk of severe breakthrough illness among vaccinated PWH and people without HIV (PWoH) who experience a breakthrough infection.

DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, the Corona-Infectious-Virus Epidemiology Team (CIVET-II) collaboration included adults (aged ≥18 years) with HIV who were receiving care and were fully vaccinated by June 30, 2021, along with PWoH matched according to date fully vaccinated, age group, race, ethnicity, and sex from 4 US integrated health systems and academic centers. Those with postvaccination COVID-19 breakthrough before December 31, 2021, were eligible.

EXPOSURES: HIV infection.

MAIN OUTCOMES AND MEASURES: The main outcome was severe COVID-19 breakthrough illness, defined as hospitalization within 28 days after a breakthrough SARS-CoV-2 infection with a primary or secondary COVID-19 discharge diagnosis. Discrete time proportional hazards models estimated adjusted hazard ratios (aHRs) and 95% CIs of severe breakthrough illness within 28 days of breakthrough COVID-19 by HIV status adjusting for demographic variables, COVID-19 vaccine type, and clinical factors. The proportion of patients who received mechanical ventilation or died was compared by HIV status.

RESULTS: Among 3649 patients with breakthrough COVID-19 (1241 PWH and 2408 PWoH), most were aged 55 years or older (2182 patients [59.8%]) and male (3244 patients [88.9%]). The cumulative incidence of severe illness in the first 28 days was low and comparable between PWoH and PWH (7.3% vs 6.7%; risk difference, -0.67%; 95% CI, -2.58% to 1.23%). The risk of severe breakthrough illness was 59% higher in PWH with CD4 cell counts less than 350 cells/μL compared with PWoH (aHR, 1.59; 95% CI, 0.99 to 2.46; P = .049). In multivariable analyses among PWH, being female, older, having a cancer diagnosis, and lower CD4 cell count were associated with increased risk of severe breakthrough illness, whereas previous COVID-19 was associated with reduced risk. Among 249 hospitalized patients, 24 (9.6%) were mechanically ventilated and 20 (8.0%) died, with no difference by HIV status.

CONCLUSIONS AND RELEVANCE: In this cohort study, the risk of severe COVID-19 breakthrough illness within 28 days of a breakthrough infection was low among vaccinated PWH and PWoH. PWH with moderate or severe immune suppression had a higher risk of severe breakthrough infection and should be included in groups prioritized for additional vaccine doses and risk-reduction strategies.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Lang R, Humes E, Coburn SB, et al. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Netw Open. 2022. PMID: 36227594. doi:10.1001/jamanetworkopen.2022.36397

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。